Modulating G-protein-coupled receptors: from traditional pharmacology to allosterics

Trends in Pharmacological Sciences

Volumn 28, Issue 8, 2007, Pages 431-437

  Gilchrist, Annette ^a  

^a Caden Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HORMONE; ION; PEPTIDE;

PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; GTP-BINDING PROTEINS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PHARMACOLOGY; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 34447620659     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.06.012     Document Type: Review

References (53)

1. De Lean A., et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255 (1980) 7108-7117
2. Samama P., et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268 (1993) 4625-4636
3. Egan C., et al. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 35 (2000) 144-150
4. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 25 (2004) 186-192
5. Perez D., and Karnik S. Multiple signaling states of G-protein-coupled receptors. Pharmacol. Rev. 57 (2005) 147-161
6. May L., et al. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1-51
7. Brink C.B., et al. Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br. J. Clin. Pharmacol. 57 (2004) 373-387
8. Costa T., and Cotecchia S. Historical review: negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol. Sci. 26 (2005) 618-624
9. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65 (2004) 2-11
10. Wieland T., and Michel M. Can a GDP-liganded G-protein be active?. Mol. Pharmacol. 68 (2005) 559-562
11. Milligan G., and Kostenis E. Heterotrimeric G-proteins: a short history. Br. J. Pharmacol. 147 suppl 1 (2006) S46-S55
12. Premont R., and Gainetdinov R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 69 (2007) 511-534
13. Seifert R., and Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366 (2002) 381-416
14. Hollinger S., and Hepler J. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol. Rev. 54 (2002) 527-559
15. Frank M., et al. G protein activation without subunit dissociation depends on a G{alpha}(i)-specific region. J. Biol. Chem. 280 (2005) 24584-24590
16. Udawela M., et al. The receptor activity modifying protein family of G protein coupled receptor accessory proteins. Semin. Cell Dev. Biol. 15 (2004) 299-308
17. Cismowski M. Non-receptor activators of heterotrimeric G-protein signaling (AGS proteins). Semin. Cell Dev. Biol. 17 (2006) 334-344
18. Sato M., et al. Accessory proteins for G proteins: partners in signaling. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 151-187
19. Sun Y., et al. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J. 26 (2007) 53-64
20. Charest P., et al. The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell. Signal. 19 (2007) 32-41
21. Hay D., et al. GPCR modulation by RAMPs. Pharmacol. Ther. 109 (2006) 173-197
22. Ferguson S. Phosphorylation-independent attenuation of GPCR signalling. Trends Pharmacol. Sci. 28 (2007) 173-179
23. Torrecilla I., and Tobin A. Co-ordinated covalent modification of G-protein coupled receptors. Curr. Pharm. Des. 12 (2006) 1797-1808
24. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66 (2004) 1-7
25. Nelson C., and Challiss R. Phenotypic pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem. Pharmacol. 73 (2007) 737-751
26. Eglen R. Emerging concepts in GPCR function-the influence of cell phenotype on GPCR pharmacology. Proc. West. Pharmacol. Soc. 48 (2005) 31-34
27. Kjelsberg M.A., et al. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J. Biol. Chem. 267 (1992) 1430-1433
28. Martel J., et al. Native rat hippocampal 5-HT1A receptors show constitutive activity. Mol. Pharmacol. 71 (2007) 638-643
29. Newman-Tancredi A., et al. Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. Mol. Pharmacol. 58 (2000) 1042-1049
30. Romero G., et al. Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists. Naunyn Schmiedebergs Arch. Pharmacol. 374 (2006) 31-39
31. Weiss J., et al. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J. Theor. Biol. 181 (1996) 381-397
32. Azzi M., et al. Allosteric effects of G protein overexpression on the binding of beta-adrenergic ligands with distinct inverse efficacies. Mol. Pharmacol. 60 (2001) 999-1007
33. Urban J., et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320 (2007) 1-13
34. Kobilka B. G protein coupled receptor structure and activation. Biochim. Biophys. Acta 1768 (2007) 794-807
35. Pineyro G., and Archer-Lahlou E. Ligand-specific receptor states: implications for opiate receptor signalling and regulation. Cell. Signal. 19 (2007) 8-19
36. Shoemaker J., et al. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J. Pharmacol. Exp. Ther. 315 (2005) 828-838
37. Conklin B., et al. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363 (1993) 274-276
38. Conklin B., et al. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. Mol. Pharmacol. 50 (1996) 885-890
39. Rasenick M., et al. Synthetic peptides as probes for G protein function. Carboxyl-terminal G alpha s peptides mimic Gs and evoke high affinity agonist binding to beta-adrenergic receptors. J. Biol. Chem. 269 (1994) 21519-21525
40. Hamm H., et al. Site of G protein binding to rhodopsin mapped with synthetic peptides from the alpha subunit. Science 241 (1988) 832-835
41. Gilchrist A., et al. Antagonists of the receptor-G protein interface block Gi-coupled signal transduction. J. Biol. Chem. 273 (1998) 14912-14919
42. Martin E., et al. Potent peptide analogues of a G protein receptor-binding region obtained with a combinatorial library. J. Biol. Chem. 271 (1996) 361-366
43. Aris L., et al. Structural requirements for the stabilization of metarhodopsin II by the C terminus of the alpha subunit of transducin. J. Biol. Chem. 276 (2001) 2333-2339
44. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2002) 323-374
45. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1 (2002) 198-210
46. Langmead C., and Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol. Sci. 27 (2006) 475-481
47. May L., and Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. 3 (2003) 551-556
48. Lewandowicz A., et al. The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms. Br. J. Pharmacol. 147 (2006) 422-429
49. Woolf P., et al. Uncovering biases in high throughput screens of G-protein coupled receptors. J. Theor. Biol. 208 (2001) 403-418
50. Knudsen L., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 937-942
51. Wess J. Allosteric binding sites on muscarinic acetylcholine receptors. Mol. Pharmacol. 68 (2005) 1506-1509
52. Porter R., et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315 (2005) 711-721
53. Dong B. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin. Ther. 27 (2005) 1725-1751